Compare INTA & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INTA | TYRA |
|---|---|---|
| Founded | 2000 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 2021 | 2021 |
| Metric | INTA | TYRA |
|---|---|---|
| Price | $24.96 | $33.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 11 |
| Target Price | $41.43 | ★ $47.50 |
| AVG Volume (30 Days) | 709.9K | ★ 964.0K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.89 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $504,120,000.00 | N/A |
| Revenue This Year | $15.91 | N/A |
| Revenue Next Year | $13.78 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 17.09 | N/A |
| 52 Week Low | $19.24 | $8.75 |
| 52 Week High | $58.79 | $40.65 |
| Indicator | INTA | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 57.92 | 44.77 |
| Support Level | $24.60 | $33.81 |
| Resistance Level | $26.51 | $33.99 |
| Average True Range (ATR) | 1.19 | 2.18 |
| MACD | 0.33 | -0.28 |
| Stochastic Oscillator | 97.68 | 26.37 |
Intapp Inc is a provider of industry-specific, cloud-based software solutions for the professional and financial services industry. It empowers private capital,g, legal, accounting, and consulting firms with the technology needed to meet rapidly changing client, investor, and regulatory requirements. Geographically, it derives a majority of its revenue from the United States and also has a presence in the United Kingdom and the Rest of the world.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.